Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...
Novartis has announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ...
Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...
A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...
Rockville, Maryland Friday, January 9, 2026, 10:00 Hrs [IST] ...
Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...
Multiple sclerosis is a disease in which the immune system erroneously attacks a protective insulation that surrounds neurons ...
Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...
Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and ...
Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback